DENALI THERAPEUTICS INC. - COMMON STOCK

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

02 Apr 2025 07:00:44 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

27 Feb 2025 15:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

06 Feb 2025 10:42:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

30 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

13 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)

08 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

06 Jan 2025 15:30:09 By Nasdaq GlobeNewswire

Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease

05 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

03 Sep 2024 07:00:27 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

14 Aug 2024 13:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

01 Aug 2024 05:45:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

03 Jun 2024 07:00:40 By Nasdaq GlobeNewswire

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

07 May 2024 15:01:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

01 May 2024 07:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

27 Feb 2024 07:05:54 By Nasdaq GlobeNewswire

Denali Therapeutics Announces $500 million Private Placement Equity Financing

27 Feb 2024 07:00:37 By Nasdaq GlobeNewswire

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

01 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

08 Jan 2024 07:00:01 By Nasdaq GlobeNewswire

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

07 Nov 2023 15:01:00 By Nasdaq GlobeNewswire